Paul M. Stewart, MD, FRCP, FMedSci, executive dean and professor of Medicine at the University of Leeds in the United Kingdom, has been named the next editor-in-chief of The Journal of Clinical Endocrinology & Metabolism (JCEM).
JCEM is the world’s leading peer-reviewed journal for endocrine clinical research and cutting-edge clinical practice information. The journal provides the latest in-depth coverage of new developments that contribute to the understanding, diagnosis, and treatment of endocrine and metabolic disorders.
“I am honored to work alongside such a respected editorial team to lead one of the most prominent journals in medicine and science,” Stewart says. “JCEM is internationally recognized for its quality outputs, and I will continue to build on this great reputation to publish groundbreaking and practice-changing research for our ever-growing global readership.”
Stewart will succeed R. Paul Robertson, MD, as editor-in-chief to serve a three-year term beginning January 1, 2020. He currently serves as an associate editor for Journal of the Endocrine Society. He has previously served on the Editorial Boards of JCEM and Endocrinology and on the Advisory Board of Endocrine Reviews. He was a former senior editor of Clinical Endocrinology.
“I enthusiastically welcome Paul Stewart to the role of editor-in-chief of JCEM,” says Society President Susan J. Mandel, MD, MPH. “Paul’s international perspective, combined with his stellar clinical research career and extensive editorial experience, well position JCEM to lead as the premier endocrinology journal.”
Stewart is a past member of the Endocrine Society Council and has served on six Endocrine Society committees over recent years. In addition to his role as University executive dean of Medicine & Health, he is an honorary consultant endocrinologist at the Leeds Teaching Hospitals NHS Trust where his clinical expertise extends to patients with pituitary and adrenal disorders and endocrine hypertension.
He supervises a translational research group which focuses on corticosteroids, specifically cortisol metabolism via 11β-hydroxysteroid dehydrogenases, and his work has led to new discoveries in hypertension, obesity, aging, and polycystic ovary syndrome.
He is a primary investigator within the National Institute for Health Research (NIHR) Biomedical Research Centre in Leeds and an Emeritus NIHR senior clinical investigator. He is a Fellow and Clinical Vice-President of the UK Academy of Medical Sciences.
JCEM publishes monthly in print and continuously online; it can be accessed at https://academic.oup.com/jcem.
Loading ...